Skip to main content

Table 1 Baseline characteristics of the patients included in study group

From: Analysis of antiviral efficacy after switching from brand to generic entecavir in patients with treatment-naïve chronic hepatitis B

Characteristic Initial treatment of ETV-Brand
Age, years 61 (52.5–68.8)
Male sex, n (%) 119/175 (68.0%)
BMI, kg/m2 24.3 (22.2–27)
Period of ETV-Brand(years) 3.2 (2.7–4.3)
WBC, × 103/μL 5.8 (4.4–7.3)
HB, g/dL 13.8 (12.7–14.6)
Platelet, × 103/μL 145 (104–191)
ALT, U/L 24 (18–32)
AST, U/L 29 (24–36)
Total bilirubin, mg/dL 0.8 (0.6–1.1)
eGFR, mL/min/1.73 m2 81.8 (78.8–87.2)
FIB-4 score 2.7 (2.2–3.0)
HBeAg-positive, n (%) 34 (19.4%)
Detectable HBV DNA level, IU/mL 14.0 (12.4–16.5)
Undetectable HBV DNA, n (%) 142/175 (81%)
  1. Data are expressed as n (%) for categorical data and as mean ± standard deviation or median (interquartile range) for continuous data
  2. ETV-Brand, entecavir-brand drugs; BMI, body mass index; WBC, white blood cell; HB, hemoglobin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; eGFR, estimated glomerular filtration rate; FIB-4, Fibrosis-4; HBeAg, Hepatitis B e antigen; HBV DNA, hepatitis B virus deoxyribonucleic acid